Piper Jaffray Downgrades Pharmacyclics (PCYC) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Piper Jaffray Downgrades Pharmacyclics (PCYC) to Neutral
May 5, 2014 11:37 AM EDT
Roth Capital affirms its Buy rating and $183 target price on Pharmacyclics Inc. (Nasdaq: PCYC) following Q1 results reported last week.
Analyst Joseph Pantginis commented, After PCYC's first full quarter as a commercial stage-company, we are impressed with Imbruvica sales so far. The company provided net product revenue guidance of $80 million for 2Q14 and $295 million for FY14. The company stressed that this is very... More
May 2, 2014 8:04 AM EDT
Pharmacyclics, Inc. (NASDAQ: PCYC) reported Q1 EPS of $0.40, $0.23 better than the analyst estimate of $0.17. Revenue for the quarter came in at $119.4 million versus the consensus estimate of $105.38 million.
Clinical Update
IMBRUVICA clinical trials are active in all regions including US, Europe, Asia Pacific, Canada and Latin America. Currently IMBRUVICA is being developed in 8 different B-cell malignancies. There are 11 Phase III clinical trials initiated with IMBRUVICA and a total of 43 trials are registered on www.clinicaltrials.gov, of these 21 are... More
May 2, 2014 7:56 AM EDT
Pharmacyclics, Inc. (NASDAQ: PCYC) trading halted with news pending.
...
More
